Industry attorneys and regulatory consultants disagree on how actively device and drug companies should be monitoring social media websites, such as Twitter, Facebook and YouTube, for discussion of product-related adverse events.
While FDA says regulations do not require broad, proactive monitoring of the Web, the agency notes that companies are expected...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?